We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Advanced Melanoma

Journal Scan / Research · July 12, 2022

Spartalizumab or Placebo Plus Dabrafenib and Trametinib in Patients With BRAF V600–Mutant Melanoma

Journal for immunotherapy of cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Journal for immunotherapy of cancer
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
J Immunother Cancer 2022 Jun 01;10(6)e004226, HA Tawbi, C Robert, JC Brase, D Gusenleitner, E Gasal, J Garrett, A Savchenko, G Görgün, KT Flaherty, A Ribas, R Dummer, D Schadendorf, GV Long, PD Nathan, PA Ascierto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading